Based on the measurements of operating efficiency obtained from Altimmune's historical financial statements, Altimmune may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Altimmune's Short Term Investments are comparatively stable compared to the past year. Inventory is likely to gain to about 32.1 K in 2026, whereas Net Debt is likely to drop (33.3 M) in 2026.
Cash Flow Balance Sheet Income Statement
Housing Crash
Credit Downgrade
Yuan Drop
Covid
Interest Hikes
Altimmune Balance Sheet Chart
At this time, Altimmune's Short Term Investments are comparatively stable compared to the past year. Inventory is likely to gain to about 32.1 K in 2026, whereas Net Debt is likely to drop (33.3 M) in 2026.
Investors should never underestimate Altimmune's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to research Altimmune's cash flow, debt, and profitability to make informed and accurate decisions about investing in Altimmune.
Understanding current and past Altimmune Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Altimmune's financial statements are interrelated, with each one affecting the others. For example, an increase in Altimmune's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Altimmune's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Altimmune. Check Altimmune's Beneish M Score to see the likelihood of Altimmune's management manipulating its earnings.
Altimmune Stock Summary
Altimmune competes with GeoVax Labs, BioLineRx, Tharimmune, Ainos, and Lipocine. Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland. Altimmune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 47 people.
Foreign Associate
Thailand
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Altimmune's earnings per share (EPS) will be for research and analysis purposes. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, this information can be used for research and educational purposes even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Altimmune's current stock value. Our valuation model uses many indicators to compare Altimmune value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Altimmune competition to find correlations between indicators driving Altimmune's intrinsic value. More Info.
Altimmune is rated third in return on equity category among its peers. It is rated fourth in return on asset category among its peers . At this time, Altimmune's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Altimmune by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Most indicators from Altimmune's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Altimmune current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Today, most investors in Altimmune Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Altimmune's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Altimmune growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Altimmune help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Altimmune. We use our internally-developed statistical techniques to arrive at the intrinsic value of Altimmune based on widely used predictive technical indicators. In general, we focus on analyzing Altimmune Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Altimmune's daily price indicators and compare them against related drivers.
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.